Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.54 |
| ▸ | PGR | P06401 | 2/20 | 0.54 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.45 |
| ▸ | FEN1 | P39748 | 9/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5239044 | 1.00 | NR3C1 (0.54) | NR3C1PGRALOX5APFEN1TRPV4 | |
| SCHEMBL2006463 | 0.84 | NR3C1 (0.49) | NR3C1PGRALOX5APFEN1CIT | |
| SCHEMBL2008840 | 0.84 | NR3C1 (0.49) | NR3C1PGRALOX5APFEN1CIT | |
| SCHEMBL2006626 | 0.81 | PDE1A (0.43) | ALOX5APFEN1CIT | |
| SCHEMBL2007136 | 0.78 | NR3C1 (0.50) | NR3C1PGRALOX5APFEN1TRPV4 | |
| SCHEMBL2007134 | 0.78 | NR3C1 (0.50) | NR3C1PGRALOX5APFEN1TRPV4 | |
| SCHEMBL5239039 | 0.74 | NR3C1 (0.43) | NR3C1PGRALOX5APFEN1TRPV4 | |
| SCHEMBL30069219 | 0.73 | CYP2A6 (0.46) | NR3C1PGRALOX5APFEN1TRPV4 | |
| SCHEMBL29501239 | 0.72 | ALOX5AP (0.50) | NR3C1PGRALOX5APFEN1FFAR4 | |
| SCHEMBL12920023 | 0.71 | NR3C1 (0.51) | NR3C1PGRALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 131/4885ALOX5AP 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.